By ANISH KOKA A recent email that arrived in my in-box a few weeks ago from an academic hailed the latest “paradigm shift” in cardiology as it relates to the management of stable angina. (Stable angina refers to chronic,non-accelerating chest pain with a moderate level… Read More »The Paradigm Shift That Wasn’t: The ISCHEMIA Trial
Hillrom will buy Bardy Diagnostics, a startup that makes a wearable ECG patch, for $375 million in cash.
Boston Scientific will acquire remote cardiac monitoring company Preventice for $925 million in cash and up to $300 million in milestone payments. The deal is expected to close in mid-2021.
Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. The US regulator is looking at data from the EMPEROR-Reduced trial of… Read More »Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
In this webinar on Feb. 10,healthcare experts from Desert Oasis Healthcare and iRhythm Technologies will discuss how Zio monitors, designed to be worn for longer duration than holter monitors, represent a new standard of care in remote cardiac monitoring.
Novartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster because a manufacturing facility has yet to be inspected. Matters appear to have been complicated by the pandemic and the travel disruption that it has caused, which… Read More »FDA rejects Novartis’ cholesterol drug after factory inspection issue
Update on Heart Rhythm Detection Devices for Remote Patient Monitoring Advances in the detection of heart rhythms using medical-grade but consumer-facing remote patient monitoring – product reviews The Doctor Weighs In
Update on Heart Rhythm Detection Devices for Remote Patient Monitoring Top Product Reviews: Advances in the detection of heart rhythms using medical-grade but consumer-facing remote patient monitoring. The Doctor Weighs In
Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 trial. An FDA advisory committee 12 to 1… Read More »Entresto set for big sales hike after FDA panel endorsement
Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial. Take a look at Amgen’s portfolio and it becomes apparent how important this potential new drug is: the… Read More »Amgen shares down as heart failure drug disappoints in phase 3 trial
UK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, which could be used as a treatment for atrial fibrillation without the need for medication. Antiarrhythmic drugs are standard therapy but they often only work for around… Read More »RHYTHM AI cleared for large trial of atrial fibrillation mapping tool
The FDA has started a speedy review of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that dramatically raises the risk of heart disease. The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is… Read More »Regeneron’s cholesterol drug evinacumab claims February FDA date
Why We Need to Unlock the Full Potential of Primary Care There are powerful reasons to move to a value-based primary care system. Highly effective Primary Care 3.0 is an indispensable piece of that effort. The Doctor Weighs In
Lecithin Supplements: Understanding the Risks and Benefits Before you take lecithin supplements, you should weigh the lack of credible evidence of benefits against scientific literature that suggests safety concerns. The Doctor Weighs In